{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:24:30Z","timestamp":1774596270309,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T00:00:00Z","timestamp":1269216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To quantify the effect of age on the incidence of osteoporosis\u2010related fractures and of risedronate treatment on fracture risk in different age groups in women with postmenopausal osteoporosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Data from four randomized, double\u2010blind, placebo\u2010controlled, Phase III studies were pooled and analyzed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    The analysis population (N=3,229) consisted of postmenopausal women with osteoporosis as determined on the basis of prevalent vertebral fractures, low bone mineral density (BMD), or both.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>INTERVENTION:<\/jats:bold>\n                    Patients had received risedronate 5\u2003mg daily or placebo for 1 to 3 years.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    The endpoints of interest were the incidence of osteoporosis\u2010related fractures, clinical fractures, nonvertebral fractures, and morphometric vertebral fractures. The effect of age on fracture risk and treatment benefit was examined using Cox regression models with age and treatment as explanatory variables. The 3\u2010year fracture risk was estimated for patients in each treatment group at a given age.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Irrespective of treatment, fracture risks were greater in older patients (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001). On average, for every 1\u2010year increase in age, a patient's risk for osteoporosis\u2010related fracture increased 3.6% (95% confidence interval=2.3\u20135.0%). Irrespective of age, risedronate treatment reduced fracture risk 42%. Risedronate\u2010treated patients had fracture risks similar to those of placebo\u2010treated patients 10 to 20 years younger.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    Patients treated with risedronate have a significantly lower fracture risk, similar to that of untreated patients 10 to 20 years younger.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2010.02763.x","type":"journal-article","created":{"date-parts":[[2010,3,22]],"date-time":"2010-03-22T15:25:14Z","timestamp":1269271514000},"page":"658-663","source":"Crossref","is-referenced-by-count":18,"title":["Assessment of the Relationship Between Age and the Effect of Risedronate Treatment in Women with Postmenopausal Osteoporosis: A Pooled Analysis of Four Studies"],"prefix":"10.1111","volume":"58","author":[{"given":"Steven","family":"Boonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea B.","family":"Klemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-006-0172-4"},{"key":"e_1_2_6_3_2","volume-title":"United Nations Deparment of Economic and Social Affairs\/Population Division. World Population to 2300","author":"United Nations.","year":"2004"},{"key":"e_1_2_6_4_2","first-page":"78","article-title":"Independent predictors of all osteoporosis\u2010related fractures in healthy postmenopausal women","volume":"32","author":"Albrand G","year":"2003","journal-title":"The OFELY study"},{"key":"e_1_2_6_5_2","first-page":"75","article-title":"Risk factors for vertebral and nonvertebral fracture over 10 years","volume":"23","author":"Finigan J","year":"2008","journal-title":"A population-based study in women"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004148"},{"key":"e_1_2_6_7_2","first-page":"285","article-title":"Hip fractures in the elderly","volume":"2","author":"Cooper C","year":"1992","journal-title":"A world-wide projection"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113"},{"key":"e_1_2_6_9_2","first-page":"1284","article-title":"Incidence of hip fracture over a 10\u2010year period (1991\u20132000)","volume":"40","author":"Chevalley T","year":"2007","journal-title":"Reversal of a secular trend"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060815"},{"key":"e_1_2_6_11_2","first-page":"18","article-title":"Changes in hip fracture epidemiology","volume":"13","author":"Lofman O","year":"2002","journal-title":"Redistribution between ages, genders and fracture types"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0742-8"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.47102\/annals-acadmedsg.V31N1p67","article-title":"Osteoporosis\u2014a worldwide problem and the implications in Asia","volume":"31","author":"Lau EM.","year":"2002","journal-title":"Ann Acad Med Singapore"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-007-0835-z"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0685-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.4.655"},{"key":"e_1_2_6_17_2","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass","volume":"85","author":"Fogelman I","year":"2000","journal-title":"Results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group"},{"key":"e_1_2_6_18_2","first-page":"1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris ST","year":"1999","journal-title":"A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group"},{"key":"e_1_2_6_19_2","first-page":"251","article-title":"Risedronate prevents bone loss in early postmenopausal women","volume":"8","author":"Hooper MJ","year":"2005","journal-title":"A prospective randomized, placebo-controlled trial"},{"issue":"3","key":"e_1_2_6_20_2","first-page":"111","article-title":"Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass (abstract 349)","volume":"8","author":"McClung M","year":"1998","journal-title":"Osteoporosis Int"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050010"},{"key":"e_1_2_6_22_2","first-page":"1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid\u2010induced osteoporosis in men and women","volume":"15","author":"Reid DM","year":"2000","journal-title":"A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440503"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2011-8"},{"key":"e_1_2_6_26_2","first-page":"1039","article-title":"Monthly dosing of 75\u2003mg risedronate on 2 consecutive days a month","volume":"19","author":"Delmas PD","year":"2008","journal-title":"Efficacy and safety results"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.09.001"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-003-0042-4"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125003125"},{"key":"e_1_2_6_30_2","volume-title":"Encyclopedia of Biostatistics","author":"Buonaccorsi J.","year":"1998"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.3.557"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.12.2214"},{"key":"e_1_2_6_33_2","volume-title":"Administration on Aging. A Profile of Older Americans: 2007","year":"2007"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.111152298"},{"key":"e_1_2_6_35_2","unstructured":"HSBC Insurance(2007). The future of retirement. The new old age [on\u2010line]. Available athttp:\/\/www.hsbc.com\/1\/PA_1_1_S5\/content\/assets\/retirement\/2007_for_report.pdfAccessed June 1 2009."},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060301"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1483-3"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1762-7"},{"key":"e_1_2_6_39_2","first-page":"695","article-title":"Sequential change in quality of life for patients with incident clinical fractures","volume":"20","author":"Hagino H","year":"2009","journal-title":"A prospective study"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1622-5"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-3-11"},{"key":"e_1_2_6_42_2","first-page":"1579","article-title":"The impact of incident vertebral and non\u2010vertebral fragility fractures on health\u2010related quality of life in established postmenopausal osteoporosis","volume":"30","author":"Oglesby AK","year":"2003","journal-title":"Results from the teriparatide randomized, placebo-controlled trial in postmenopausal women"},{"key":"e_1_2_6_43_2","first-page":"1633","article-title":"Excess mortality following hip fracture","volume":"20","author":"Abrahamsen B","year":"2009","journal-title":"A systematic epidemiological review"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.50"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)90022-X"},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2106\/00004623-200104000-00003","article-title":"The economic cost of hip fractures among elderly women. A one\u2010year, prospective, observational cohort study with matched\u2010pair analysis. Belgian Hip Fracture Study Group","volume":"83","author":"Haentjens P","year":"2001","journal-title":"J Bone Jt Surg Am"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2003.51110.x"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2007.07.012"},{"key":"e_1_2_6_49_2","first-page":"87","article-title":"Functional outcome and quality of life following hip fracture in elderly women","volume":"15","author":"Boonen S","year":"2004","journal-title":"A prospective controlled study"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-1383(02)00414-X"},{"key":"e_1_2_6_51_2","unstructured":"U.S. National Center for Health Statistics.U.S. National Center for Health Statistics National Vital Statistics Reports (NVSR) Deaths: Final Data for 2005 Vol. 56 No. 10 April 24 2008 [on\u2010line]. Available athttp:\/\/www.census.gov\/compendia\/statab\/tables\/09s0100.pdfAccessed January 9 2009."}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2010.02763.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2010.02763.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:21:22Z","timestamp":1762176082000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2010.02763.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1532-5415.2010.02763.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02763.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}